WASHINGTON — Some House Democrats are raising new concerns about a landmark Trump administration trade agreement, implying that it will weaken the bipartisan effort to lower prescription drug prices.
But experts tell STAT that the treaty won’t actually increase prices or stifle competition in the U.S.
